查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1472023

肌腱炎治療市場 - 依治療（治療、手術、藥物）、應用（阿基里斯腱炎、岡上肌腱炎、網球肘、投手肘、跳投膝）、配銷通路、最終用途 - 全球預測 2024 - 2032

Tendonitis Treatment Market - By Treatment (Therapy, Surgery, Medication), Application (Achilles Tendonitis, Supraspinatus Tendonitis, Tennis Elbow, Pitchers Elbow, Jumpers Knee), Distribution Channel, End-use - Global Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 230 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

在領先公司不斷加強研發力度的推動下，2024 年至 2032 年間，全球肌腱炎治療市場複合年成長率將達到 3.8%。由於肌腱炎是一種影響全球數百萬人的普遍疾病，因此越來越需要能夠提供有效緩解和更快恢復的創新治療方法。

例如，2023 年 6 月，梅奧診所的物理醫學和復健專家正在利用超音波引導進行經皮腱切斷術，採用高壓鹽水流來治療慢性肌腱病患者。這種門診手術稱為經皮加壓水腱切開術，不需要全身麻醉。

領先的製藥和生技公司正在大力投資研發，以開發新型療法，包括再生醫學方法和先進的藥物配方。此外，穿戴式裝置和微創手術等技術進步正在重塑肌腱炎治療的模式。隨著這些努力取得了可喜的成果，肌腱炎治療市場有望顯著成長，為患者帶來希望，並推動針對這種常見疾病的醫療保健解決方案的發展。

整個肌腱炎治療行業根據治療、應用、配銷通路、最終用途和地區進行分類。

2024年至2032年，手術部分將經歷顯著發展。經皮腱切斷術或肌腱修復術等手術為恢復肌腱功能和減輕症狀提供了有效的解決方案。隨著微創技術的進步和手術效果的改善，患者和醫療保健提供者越來越傾向於手術治療。因此，肌腱炎治療市場對手術介入的需求持續擴大，滿足了尋求長期緩解和提高生活品質的個人的需求。

從2024 年到2032 年，岡上肌腱炎細分市場的肌腱炎治療市場佔有率將出現顯著的複合年成長率。並恢復功能。保守方法（例如休息、物理治療和非類固醇抗發炎藥）以及更先進的治療方法（包括皮質類固醇注射或手術干預）都旨在解決這種情況。為了減輕疼痛並改善肩部活動能力，肌腱炎治療市場對針對岡上肌腱炎的創新和客製化治療的需求仍然很高。

亞太地區肌腱炎治療市場從2024 年到2032 年將呈現出值得稱讚的複合年成長率。對有效治療方案的需求日益成長。此外，醫療保健意識的提高、醫療設施的改善以及治療方式的進步都有助於擴大市場需求。隨著亞太地區醫療基礎設施的不斷發展，對肌腱炎治療的需求可能會穩步成長，以滿足不斷成長的人口的需求。例如，2024年3月，由中國科學院上海矽酸鹽研究所領導的一個中國研究團隊設計了一個使用無機生物陶瓷的多細胞支架來解決肌腱到骨骼的損傷。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 運動相關損傷的發生率不斷上升
      • 骨相關疾病的發生率上升
      • 科技不斷進步
      • 增強身體健康意識
    • 產業陷阱與挑戰
      • 肌腱炎治療費用虛高
      • 缺乏報銷場景
  • 成長潛力分析
  • 監管環境
  • 技術景觀
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 競爭定位矩陣

第 5 章：市場估計與預測：按處理方式，2018 - 2032

  • 主要趨勢
  • 治療
    • 冷熱療法
    • 物理治療
    • 衝擊波療法
  • 手術
  • 藥物
    • 口服
    • 專題

第 6 章：市場估計與預測：按應用分類，2018 年 - 2032 年

  • 主要趨勢
  • 跟腱炎
  • 岡上肌腱炎
  • 網球肘
  • 投手肘部
  • 跳投者的膝蓋

第 7 章：市場估計與預測：按配銷通路，2018 年 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第 8 章：市場估計與預測：按最終用途，2018 - 2032 年

  • 主要趨勢
  • 醫院
  • 專科診所
  • 家庭護理設置
  • 其他最終用戶

第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 10 章：公司簡介

  • Abbott Laboratories
  • AstraZeneca
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bristol Myers Squibb Company
  • Colfax Corporation
  • GalxoSmithKline AG
  • Johnson & Johnson
  • Merck and Co., Inc.
  • Ossur
  • Pifzer Inc.
  • Stryker Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Tynor Orthotics Pvt. Ltd
  • Zimmer Biomet Holdings, Inc.
簡介目錄
Product Code: 8326

Global Tendonitis Treatment Market will witness 3.8% CAGR between 2024 and 2032, fueled by increasing research and development efforts from leading companies. With tendonitis being a prevalent condition affecting millions globally, there is a growing need for innovative treatments that offer effective relief and faster recovery.

For instance, in June 2023, Physical medicine and rehabilitation specialists at Mayo Clinic are utilizing ultrasound guidance for percutaneous tenotomies, employing a high-pressure saline stream to treat individuals with chronic tendinopathy. Referred to as percutaneous pressured hydrotenotomy, this outpatient procedure did not necessitate general anesthesia.

Leading pharmaceutical and biotech companies are investing heavily in R&D to develop novel therapies, including regenerative medicine approaches and advanced drug formulations. Additionally, technological advancements such as wearable devices and minimally invasive procedures are reshaping the landscape of tendonitis treatment. As these efforts yield promising results, the market for tendonitis treatments is poised for significant growth, offering hope for patients and driving the evolution of healthcare solutions tailored to address this common ailment.

The overall Tendonitis Treatment Industry is classified based on the treatment, application, distribution channel, end-use, and region.

The surgery segment will undergo notable development from 2024 to 2032. Surgery remains a crucial option for patients with severe or refractory tendonitis cases, particularly when conservative treatments fail to provide relief. Procedures such as percutaneous tenotomies or tendon repairs offer effective solutions for restoring tendon function and alleviating symptoms. With advancements in minimally invasive techniques and improved surgical outcomes, there is a growing preference for surgical treatments among patients and healthcare providers. As a result, the demand for surgical interventions in the tendonitis treatment market continues to expand, addressing the needs of individuals seeking long-term relief and improved quality of life.

The tendonitis treatment market share from the supraspinatus tendonitis segment will register a noteworthy CAGR from 2024 to 2032. As a common cause of shoulder pain, supraspinatus tendinitis requires effective treatment options to alleviate discomfort and restore function. Both conservative approaches, such as rest, physical therapy, and NSAIDs, as well as more advanced treatments, including corticosteroid injections or surgical interventions, are sought to address this condition. To reduce pain and improve shoulder mobility, the demand for innovative and tailored treatments targeting supraspinatus tendinitis remains high in the tendonitis treatment market.

Asia Pacific tendonitis treatment market will showcase a commendable CAGR from 2024 to 2032. With a large population and increasing prevalence of tendonitis-related conditions due to aging, physical activity, and occupational hazards, there is a growing need for effective treatment options. Moreover, rising healthcare awareness, improving access to medical facilities, and advancements in treatment modalities contribute to the expanding market demand. As healthcare infrastructure continues to develop across the Asia-Pacific region, the demand for tendonitis treatments could rise steadily to meet the needs of the growing population. For instance, in March 2024, a Chinese research group led by the Shanghai Institute of Ceramics of the Chinese Academy of Sciences devised a multicellular scaffold using inorganic bioceramics to address tendon-to-bone injuries.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data sources
    • 1.5.1 Primary
    • 1.5.2 Secondary
      • 1.5.2.1 Paid sources
      • 1.5.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of sports related injuries
      • 3.2.1.2 Rising incidence of bone related disorders
      • 3.2.1.3 Growing technological advancements
      • 3.2.1.4 Increasing awareness regarding physical fitness
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Inflated of cost of tendonitis treatment
      • 3.2.2.2 Lack of reimbursement scenario
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix

Chapter 5 Market Estimates and Forecast, By Treatment, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Therapy
    • 5.2.1 Hot & cold therapy
    • 5.2.2 Physical therapy
    • 5.2.3 Shockwave therapy
  • 5.3 Surgery
  • 5.4 Medications
    • 5.4.1 Oral
    • 5.4.2 Topical

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Achilles tendonitis
  • 6.3 Supraspinatus tendonitis
  • 6.4 Tennis elbow
  • 6.5 Pitcher's elbow
  • 6.6 Jumper's knee

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospital pharmacy
  • 7.3 Retail pharmacy
  • 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Specialty clinics
  • 8.4 Home care settings
  • 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 AstraZeneca
  • 10.3 Boehringer Ingelheim Pharmaceuticals, Inc.
  • 10.4 Bristol Myers Squibb Company
  • 10.5 Colfax Corporation
  • 10.6 GalxoSmithKline AG
  • 10.7 Johnson & Johnson
  • 10.8 Merck and Co., Inc.
  • 10.9 Ossur
  • 10.10 Pifzer Inc.
  • 10.11 Stryker Corporation
  • 10.12 Teva Pharmaceutical Industries Ltd.
  • 10.13 Tynor Orthotics Pvt. Ltd
  • 10.14 Zimmer Biomet Holdings, Inc.